Bank OZK Has $1.15 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Bank OZK lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 5.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,808 shares of the company’s stock after purchasing an additional 287 shares during the period. Bank OZK’s holdings in Zoetis were worth $1,146,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of ZTS. Vaughan Nelson Investment Management L.P. acquired a new position in Zoetis in the 3rd quarter valued at about $176,219,000. Alphinity Investment Management Pty Ltd grew its stake in Zoetis by 214.7% in the 4th quarter. Alphinity Investment Management Pty Ltd now owns 824,148 shares of the company’s stock valued at $162,662,000 after buying an additional 562,259 shares during the last quarter. International Assets Investment Management LLC grew its stake in Zoetis by 27,671.0% in the 4th quarter. International Assets Investment Management LLC now owns 479,328 shares of the company’s stock valued at $94,605,000 after buying an additional 477,602 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in Zoetis by 34.8% in the 3rd quarter. Envestnet Asset Management Inc. now owns 1,562,044 shares of the company’s stock valued at $271,764,000 after buying an additional 403,164 shares during the last quarter. Finally, Natixis Advisors L.P. grew its stake in Zoetis by 53.9% in the 3rd quarter. Natixis Advisors L.P. now owns 941,219 shares of the company’s stock valued at $163,753,000 after buying an additional 329,543 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of Zoetis stock traded up $5.06 on Friday, reaching $158.42. 5,236,463 shares of the stock were exchanged, compared to its average volume of 4,019,007. The firm’s 50 day moving average is $171.79 and its 200-day moving average is $179.29. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. The firm has a market cap of $72.45 billion, a PE ratio of 31.25, a P/E/G ratio of 2.34 and a beta of 0.85.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. Zoetis’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.15 earnings per share. As a group, analysts anticipate that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be given a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 1.09%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio is 34.12%.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the transaction, the executive vice president now directly owns 15,723 shares in the company, valued at approximately $2,725,267.59. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold a total of 2,209 shares of company stock worth $371,293 in the last three months. 0.12% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Piper Sandler reiterated an “overweight” rating and issued a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Stifel Nicolaus cut their price objective on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd. StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Barclays cut their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday. Finally, The Goldman Sachs Group boosted their price objective on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $218.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.